Skip to main content
DIRUI INDUSTRIAL CO.,LTD. logo

DIRUI INDUSTRIAL CO.,LTD. — Investor Relations & Filings

Ticker · 300396 ISIN · CNE100001XS7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,690 across all filing types
Latest filing 2015-06-01 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300396

About DIRUI INDUSTRIAL CO.,LTD.

https://www.dirui.com.cn

DIRUI INDUSTRIAL CO.,LTD. specializes in the research, development, manufacturing, and distribution of medical laboratory instruments and diagnostic reagents. The company provides comprehensive solutions for in-vitro diagnostics (IVD), focusing on several key clinical areas including urinalysis, biochemistry, hematology, and chemiluminescence immunoassay. Its product portfolio features high-throughput automated analyzers and integrated laboratory systems designed to enhance diagnostic efficiency and accuracy. DIRUI serves a global market, providing medical institutions and laboratories with a wide range of diagnostic tools, from urine sediment analysis to vaginal secretion testing. The company emphasizes technological innovation and quality control to support clinical decision-making and patient care through reliable laboratory automation and standardized testing protocols.

Recent filings

Filing Released Lang Actions
关于变更募集资金投资项目的可行性研究报告
Capital/Financing Update Classification · 95% confidence The document is a detailed feasibility study report regarding changes in the investment projects funded by raised capital. It discusses the use of proceeds from an IPO, acquisition of a company (宁波瑞源生物科技有限公司), financial data of the target company, changes in investment plans, strategic and financial analysis, risk factors, and compliance with regulatory requirements. The content focuses on the use and adjustment of raised funds, acquisition details, and investment project changes rather than being a full annual or interim financial report. It is not a simple announcement or a brief summary but a comprehensive report on the feasibility and impact of changing the use of raised capital. This fits the category of a Capital/Financing Update (CAP), as it provides updates on fundraising usage and capital structure changes related to the acquisition and investment projects. The document length (15,000 characters) and detailed financial and strategic analysis support this classification with high confidence.
2015-06-01 Chinese
董事会关于公司股票价格波动是否达到《关于规范上市公司信息披露及相关各方行为的通知》（证监公司字[2007]128号）第五条相关标准的说明
Regulatory Filings Classification · 95% confidence The document is a statement from the board of directors regarding whether the company's stock price fluctuation meets the criteria set by a regulatory notice (证监公司字[2007]128号) related to information disclosure and insider trading investigation thresholds. It provides stock price data and analysis for a specific 20 trading day period before a trading suspension. The document is an explanatory announcement about stock price behavior and regulatory compliance, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial data. It is also not a voting result, director dealing, or capital change announcement. Given the regulatory context and the nature of the content, this fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements and compliance documents that do not fit other categories. The document length is short (1021 characters), and it is a standalone explanation rather than a report publication announcement or certification letter. Therefore, the classification is RNS with high confidence.
2015-06-01 Chinese
独立董事意见
Regulatory Filings Classification · 95% confidence The document is titled as an "Independent Directors' Opinion" from Changchun Dirui Medical Technology Co., Ltd. It discusses the independent directors' review and approval of a major asset purchase plan, including the evaluation of the transaction's fairness, compliance with laws and regulations, and the use of raised funds for the acquisition. The document is a formal opinion statement by independent directors regarding a specific transaction and related asset evaluation, not a full financial report or earnings release. It does not contain financial statements or comprehensive financial data but rather an independent opinion on a corporate transaction. This type of document is typically classified under Regulatory Filings (RNS) as it is a compliance-related disclosure and does not fit into other categories such as Annual Report, Interim Report, or Capital/Financing Update. The document length is 2249 characters, which is relatively short and consistent with an opinion or statement rather than a full report.
2015-06-01 Chinese
独立董事关于公司重大资产购买事项的事先认可意见
M&A Activity Classification · 95% confidence The document is an independent directors' prior approval opinion regarding a major asset acquisition by the company. It discusses the company's plan to acquire 51% equity of another company, the review and approval process by the board and shareholders, and the fairness and strategic fit of the transaction. This is a formal opinion related to a significant transaction, not a full report or announcement of voting results. It is not a general regulatory filing or a report publication announcement. The content fits best under M&A Activity (TAR) as it relates to merger/acquisition transaction documentation and approvals.
2015-06-01 Chinese
拟收购宁波瑞源生物科技有限公司的股权项目涉及的宁波瑞源生物科技有限公司股东全部权益价值资产评估报告
Capital/Financing Update Classification · 95% confidence The document is a detailed asset valuation report related to a proposed acquisition of equity in Ningbo Ruiyuan Biotechnology Co., Ltd. by Changchun Dirui Medical Technology Co., Ltd. It includes an asset appraisal report, valuation methods, audit opinions, company background, and detailed financial and ownership information. The document is lengthy (15,000 characters) and contains substantive financial data, valuation conclusions, and audit references. It is not a brief announcement or a certification letter but a full asset evaluation report used to support a capital transaction (equity acquisition). This fits best under the category of Capital/Financing Update (CAP), as it relates to a financing activity (equity acquisition) and provides detailed valuation information to support that transaction. It is not an Annual Report, Audit Report, or Merger & Acquisition filing per se, but a valuation report supporting a capital transaction. Therefore, the most appropriate classification is CAP with high confidence.
2015-06-01 Chinese
国信证券股份有限公司关于公司变更募集资金用途的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from Guosen Securities regarding the change in the use of raised funds by Changchun Dirui Medical Technology Co., Ltd. It references regulatory rules related to securities issuance and listing, details the original fundraising, the projects funded, and the proposed changes including acquisition of a 51% stake in another company. The document includes financial data of the target company, audit reports, and approvals from the board and independent directors. It is a formal verification and opinion report by the sponsor on the change of use of proceeds from a prior fundraising event. This fits the category of Capital/Financing Update (CAP) as it concerns changes in the use of raised capital and related financing activities. The document is substantive and not merely an announcement or certification, and it is not a full annual or interim report, nor a regulatory filing or announcement. Therefore, the best classification is CAP with high confidence.
2015-06-01 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.